BioSpace News Archive

Benchmark Appointed Key Manufacturing Partner To Scale Delivery of DnaNudge’s RT-PCR Test, Now In Major Global Demand to Aid Fight Against COVID-19

Scientific Advisory Board Member Dr. Joseph F. O’Donnell Steps in as Interim Chief Medical Officer; Jason Summa Joins in Newly Created Clinical Development Role

Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors

Peptilogics announced that the US Food and Drug Administration has granted Orphan Drug Designation for PLG0206, the company’s first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic joint infections, a rare life-threatening condition that may result from arthroplasty or joint replacement procedures.

Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology intratumoral microdosing platform, announced a new research collaboration with Takeda Pharmaceutical Company Limited that will utilize CIVO to evaluate multiple investigational oncology agents and combinations in Phase 0 trials.

Phio Pharmaceuticals Corp. announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year from September 14 – 16, 2020.

TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies in oncology, announced plans to file two Investigational New Drug applications in their liquid tumor program in 2021.

Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster

Repare Therapeutics Inc. announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15 at 10:15 a.m.

Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd., announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.